Eiger Biopharmaceuticals (NASDAQ: EIGR) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Eiger Biopharmaceuticals and Agenus, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eiger Biopharmaceuticals 0 0 7 0 3.00
Agenus 0 1 2 0 2.67

Eiger Biopharmaceuticals currently has a consensus target price of $29.00, indicating a potential upside of 222.22%. Agenus has a consensus target price of $6.33, indicating a potential upside of 69.34%. Given Eiger Biopharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eiger Biopharmaceuticals is more favorable than Agenus.

Valuation & Earnings

This table compares Eiger Biopharmaceuticals and Agenus’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eiger Biopharmaceuticals N/A N/A -$47.08 million ($5.30) -1.70
Agenus $22.57 million 16.90 -$126.99 million ($1.17) -3.20

Eiger Biopharmaceuticals has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than Eiger Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

47.1% of Eiger Biopharmaceuticals shares are held by institutional investors. Comparatively, 37.9% of Agenus shares are held by institutional investors. 28.8% of Eiger Biopharmaceuticals shares are held by insiders. Comparatively, 7.9% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Eiger Biopharmaceuticals and Agenus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eiger Biopharmaceuticals N/A -169.16% -95.71%
Agenus -278.76% N/A -65.18%

Risk and Volatility

Eiger Biopharmaceuticals has a beta of 2.55, meaning that its stock price is 155% more volatile than the S&P 500. Comparatively, Agenus has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.

Summary

Eiger Biopharmaceuticals beats Agenus on 8 of the 12 factors compared between the two stocks.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Agenus Company Profile

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.